Latest News and Press Releases

Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable disease was observed in 10 of 27 evaluable...

HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...

AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated...

HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...

Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncologyScientific Advisory Board to provide guidance on...

AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational statusStudy demonstrated specific anti-tumor response even at low levels of...

AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022AFM13 combination with NK...

Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumorsDesign and rationale of the phase 1/2a study of...

HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...

HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...